IGF::OT::IGF SBIR TOPIC 66 PHASE II: HAPTOGLOBIN TREATMENT TO REDUCE COMPLICATIONS OF SICKLE CELL DISEASE

Information

  • Research Project
  • 8926510
  • ApplicationId
    8926510
  • Core Project Number
    N44HB000000
  • Full Project Number
    268201400032C-0-0-1
  • Serial Number
  • FOA Number
  • Sub Project Id
  • Project Start Date
    7/1/2014 - 10 years ago
  • Project End Date
    6/30/2015 - 9 years ago
  • Program Officer Name
  • Budget Start Date
    -
  • Budget End Date
    -
  • Fiscal Year
    2014
  • Support Year
  • Suffix
  • Award Notice Date
    -
Organizations

IGF::OT::IGF SBIR TOPIC 66 PHASE II: HAPTOGLOBIN TREATMENT TO REDUCE COMPLICATIONS OF SICKLE CELL DISEASE

Complications of Sickle Cell Disease may potentially be treated by the use of haptoglobin to bind and remove free hemoglobin from the circulation. Free hemoglobin causes oxidative stress and attendant vascular and tissue complications. Haptoglobin binding of free hemoglobin helps prevent entry of free hemoglobin into the kidney and to pass through the vascular endothelium. The development of innovative methodologies to bind and remove free hemoglobin from the circulation may provide a novel therapeutic approach for the management of complications of Sickle Cell Disease.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    N44
  • Administering IC
    HL
  • Application Type
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    649748
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:649748\
  • Funding Mechanism
    SBIR/STTR Contracts
  • Study Section
  • Study Section Name
  • Organization Name
    NANOSHELL COMPANY, LLC
  • Organization Department
  • Organization DUNS
    555806004
  • Organization City
    NORTH SALT LAKE
  • Organization State
    UT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    840543032
  • Organization District
    UNITED STATES